Address
201 Redwood Shores Parkway
Redwood City, CA 94065
United States of America (the)
Phone
650 206 4507
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
January 14, 2013
| Name | Title | Pay | Year Born |
| Nevan Charles Elam | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | 1.08M | 1967 |
| Daron G. Evans | Chief Financial & Business Officer | 699,209 | 1974 |
| Brian Kenneth Roberts | Chief Medical Officer | 767,526 | 1976 |
| Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | 0 | N/A |
| Chris Milks | Vice President & Head of Finance | 0 | N/A |
| Melissa Quinn | Senior Director of People and Culture | 0 | N/A |
| Robyn Sweinhart | Vice President & Head of Quality | 0 | N/A |
| Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | 0 | N/A |
| Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | 0 | N/A |
| Michael R. Deperro | Senior VP & Head of Operations | 0 | N/A |
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.